Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted DLI for Relapse Prevention in Pediatric Hematologic Malignancy
NCT05009719Phase 2Completed
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of donor lymphocytes in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), sponsored by First Saint Petersburg State Medical University. Started Apr 2021; status: completed.
02
Drugs
donor lymphocytes
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)juvenile myelomonocytic leukemia (JMML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05009719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05009719.